Conmed Stock Performance
| CNMD Stock | USD 60.61 0.78 1.27% |
The firm shows a Beta (market volatility) of 0.83, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, CONMED's returns are expected to increase less than the market. However, during the bear market, the loss of holding CONMED is expected to be smaller as well. At this point, CONMED has a negative expected return of -0.2%. Please make sure to confirm CONMED's maximum drawdown, daily balance of power, relative strength index, as well as the relationship between the skewness and day typical price , to decide if CONMED performance from the past will be repeated in the future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days CONMED has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's primary indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (1.51) | Five Day Return 2.45 | Year To Date Return (10.22) | Ten Year Return 17.54 | All Time Return 17.7 K |
Forward Dividend Yield 0.0136 | Payout Ratio | Last Split Factor 3:2 | Forward Dividend Rate 0.8 | Dividend Date 2025-04-04 |
| CONMED dividend paid on 3rd of January 2025 | 01/03/2025 |
1 | Should Value Investors Buy CONMED Stock | 01/08/2025 |
2 | Acquisition by Moller Andrew James of 5000 shares of CONMED at 71.18 subject to Rule 16b-3 | 01/27/2025 |
3 | Heres Why You Should Retain CONMED Stock in Your Portfolio for Now - MSN | 01/31/2025 |
4 | CONMED Issues Quarterly Earnings Results, Beats Expectations By 0.14 EPS | 02/07/2025 |
5 | Principal Financial Group Inc. Purchases 4,343 Shares of CONMED Co. - MarketBeat | 02/21/2025 |
6 | Endoscopic Ultrasonography Market to Hit USD 1.93 Billion by 2029 with 7.1 percent CAGR MarketsandMarkets | 02/25/2025 |
7 | Carpal Tunnel Release Systems Market to Exceed US 1,036.4 Million by 2035, Driven by Minimally Invasive Advances and Aging Population Latest Report by Transpare... | 02/26/2025 |
8 | CONMED Is Due To Pay A Dividend Of 0.20 | 02/28/2025 |
9 | Acquisition by Peter Shagory of 26127 shares of CONMED at 58.33 subject to Rule 16b-3 | 03/03/2025 |
10 | Acquisition by Todd Garner of 61475 shares of CONMED at 58.33 subject to Rule 16b-3 | 03/05/2025 |
11 | Conmed Down 12.2 percent Since Last Earnings Report Can It Rebound | 03/07/2025 |
12 | Ex-Dividend Reminder Gilead Sciences, CONMED and Thermo Fisher Scientific - Nasdaq | 03/12/2025 |
| Begin Period Cash Flow | 24.3 M |
CONMED |
CONMED Relative Risk vs. Return Landscape
If you would invest 6,956 in CONMED on December 19, 2024 and sell it today you would lose (895.00) from holding CONMED or give up 12.87% of portfolio value over 90 days. CONMED is currently does not generate positive expected returns and assumes 2.3809% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than CONMED, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CONMED Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CONMED's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CONMED, and traders can use it to determine the average amount a CONMED's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0861
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CNMD |
Estimated Market Risk
| 2.38 actual daily | 21 79% of assets are more volatile |
Expected Return
| -0.2 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average CONMED is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CONMED by adding CONMED to a well-diversified portfolio.
CONMED Fundamentals Growth
CONMED Stock prices reflect investors' perceptions of the future prospects and financial health of CONMED, and CONMED fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CONMED Stock performance.
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0432 | ||||
| Profit Margin | 0.10 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 2.7 B | ||||
| Shares Outstanding | 30.91 M | ||||
| Price To Earning | 188.03 X | ||||
| Price To Book | 1.89 X | ||||
| Price To Sales | 1.45 X | ||||
| Revenue | 1.31 B | ||||
| Gross Profit | 733.03 M | ||||
| EBITDA | 272.18 M | ||||
| Net Income | 132.42 M | ||||
| Cash And Equivalents | 33.35 M | ||||
| Cash Per Share | 1.09 X | ||||
| Total Debt | 905.78 M | ||||
| Debt To Equity | 1.45 % | ||||
| Current Ratio | 2.75 X | ||||
| Book Value Per Share | 31.15 X | ||||
| Cash Flow From Operations | 166.97 M | ||||
| Earnings Per Share | 4.25 X | ||||
| Market Capitalization | 1.9 B | ||||
| Total Asset | 2.31 B | ||||
| Retained Earnings | 560.28 M | ||||
| Working Capital | 361.88 M | ||||
| Current Asset | 393.34 M | ||||
| Current Liabilities | 119.72 M | ||||
About CONMED Performance
By analyzing CONMED's fundamental ratios, stakeholders can gain valuable insights into CONMED's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CONMED has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CONMED has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 220.48 | 137.98 | |
| Return On Tangible Assets | 0.15 | 0.08 | |
| Return On Capital Employed | 0.10 | 0.09 | |
| Return On Assets | 0.06 | 0.04 | |
| Return On Equity | 0.14 | 0.07 |
Things to note about CONMED performance evaluation
Checking the ongoing alerts about CONMED for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CONMED help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CONMED generated a negative expected return over the last 90 days | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Ex-Dividend Reminder Gilead Sciences, CONMED and Thermo Fisher Scientific - Nasdaq |
- Analyzing CONMED's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CONMED's stock is overvalued or undervalued compared to its peers.
- Examining CONMED's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CONMED's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CONMED's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CONMED's stock. These opinions can provide insight into CONMED's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CONMED Stock analysis
When running CONMED's price analysis, check to measure CONMED's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CONMED is operating at the current time. Most of CONMED's value examination focuses on studying past and present price action to predict the probability of CONMED's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CONMED's price. Additionally, you may evaluate how the addition of CONMED to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |